Novel Directions for Effective Treatments of Malignant Brain Tumors, Particularly Glioblastoma, Indicated by In Vivo Observations

Dear Colleagues,

The standard treatment of glioblastoma, the most common malignant brain tumor, is not entirely effective; therefore, this Special Issue aims to address fundamental neoplastic mechanisms and the pathogenesis of the disease initiated by treatment. We welcome the submission of original manuscripts to this Special Issue, aiming to develop more effective therapeutic approaches. Of particular interest are in vivo studies, particularly preclinical experiments, clinical studies, and case reports addressing novel treatments and imaging strategies.

Specifically, we aim to cover two areas of glioblastomas: malignant mechanisms in glioblastoma, particularly aggressive invasive behavior, and the high rate of tumor cell proliferation. We invite the submission of studies that address (1) the inhibition of metalloproteinases by agents able to cross the blood–brain barrier, (2) the effective killing of tumor cells by agents or other strategies delivered to the brain, and (3) the imaging of intact and treated glioblastoma.

We also invite studies that address the severity of the white matter inflammation initiated by trauma that is associated with surgical resection of the tumor and propagated by a multitude of postsurgical irradiations. Furthermore, studies addressing therapeutic strategies used to limit the severity of vasogenic edema associated with inflammation are also of interest for this Special Issue.

Dr. Jacek M. Kwiecien
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.